Q-omics provides the consensus-scored TPO profile across patient tissues and cancer cell-line models. TPO expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TPO is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TPO RNA expression shows 13,122 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, THCA, and BRCA as cancer lineages where TPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPO survival associations across molecular data types. TPO RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPO RNA expression–survival associations across cancer types. High TPO expression shows unfavorable associations in OV, UCEC and BLCA, but favorable associations in HNSC, BRCA and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TPO RNA expression.
This table summarizes TPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPO shows lower tumor expression in THCA, BLCA, COAD and BRCA and higher tumor expression in LUAD and KIRC. The THCA box plot shows higher TPO RNA expression in normal versus tumor tissue (log2 FC = −8.793, t-test p < 0.001).
This table shows molecular features associated with TPO in patient tissues and cancer cell lines. In patient samples, TPO shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
